Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders

Executive Summary

Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.

You may also be interested in...



Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?

Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.

Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius

Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.

Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid

Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel